New research suggests that lyserformic acid diethylamide (LSD), also known as acid, is possible. Reduces anxiety.
This marks the first trial to assess the safety and efficacy of MM120 (Pharmaceutical formulations) LSDas monotherapy for patients with moderate to severe systemic anxiety disorder, according to Daniel Karlin (MD), chief medical officer of Mindmed, a New York biopharmaceutical company.
This study was published in the Journal of the American Medical Association.
The key to longevity may be linked to surprising substances, research suggests
Nearly 200 adults between the ages of 18 and 74 According to a press release, they received one oral dose of LSD with various DOs for three months or a three-month placebo “dummy pill.”
Dosing sessions were conducted individually in private rooms with two trained monitors, where participants were observed for at least 12 hours. No psychotherapy was provided.
The researchers tracked changes in participants.” Anxiety score Weeks 1, 2, 4, 8, 12th and 4th serve as the main points of the assessment.
Four weeks later, patients who received the highest dose had significantly lower anxiety scores than the others.
Over the course of 12 weeks, 65% of patients taking 100 milligrams showed benefits, with almost 50% remission from anxiety.
The researchers also tested the effects of LSD on depression and found that the highest dose was associated with a significant improvement.
Carlin shared that the effects of LSD are almost immediate. Side effects of psychedelics include hallucinations and nausea And a headache.
The effect is dose-dependent, with 100 milligrams being the optimal dose. The 200 milligram dose also significantly surpassed the placebo. Doses of 25 and 50 milligrams showed no major advantages.
According to Karlin, one possible study complication was “functional binding,” which allowed participants to correctly infer that they had received active medication against a placebo.
A single dose of “magic mushrooms” provides five years of depression relief, researchers found
Drugmakers are planning two major large-scale implementations. Second semester exam Patients are followed for longer periods.
If the study is deemed successful, MindMed will submit the drug to the US Food and Drug Administration for approval.
LSD is classified as a I Drug ScheduleAccording to drug enforcement agencies, that means there is a high possibility of abuse and medical use is considered unacceptable.
Schedule I drugs are not legally permitted to be prescribed, dispensed or used in treatment, except in approved studies.
The FDA has designated LSD, psilocybin, and MDMA as “potentials.” A groundbreaking treatment“Dr. Marc Siegel, senior medical analyst at Fox News, told Fox News Digital.
Miley Cyrus reveals “powerful” therapy that helped her fears on the conquest stage
“What’s important is careful surveillance and meticulous research that monitors both side effects and efficacy,” Siegel said.
The new study shows “very positive results in around 200 patients,” but Siegel confirmed that LSD can cause hallucinations.
Additional documented side effects include paranoia, mood swing, and Increased heart rate According to multiple sources, long-term mental illness.
Hadas Alterman, a psychedelic medical attorney in Washington, DC, told Fox News Digital that “LSD return is not cultural or scientific, it is a regulation.”
Experts say the psychedelics were “standing by the sidelines” because of “a fundamental expansion of FDA authorities under the 1962 Kefferber Harris revision.”
Click here to sign up for our health newsletter
The law, also known as the amendment to drug efficacy, required drug manufacturers to provide substantial evidence of efficacy Well-controlled clinical trials Before approval.
“LSD and other psychedelics have long shown clinical promises, but the excessive use of recreation in the 1960s has slowed researchers from continuing to study it,” Siegel added.
Robert F. Kennedy Jr. of the Department of Health and Human Services and Doug Collins, Director of Veterans Affairs, are interested in exploring psychedelic therapy.
Visit us for more health articles www.foxnews.com/health
“This line of treatment is Clinical environmentand we’re working very hard to make sure it happens within 12 months,” RFK recently told council members on AP by AP.
Psychedelic advocate Alterman pointed out that support “is not a replacement for science,” while encouraging agencies like the FDA to “take this seriously.”
